FDA Accepts BLA for Odronextamab in Treating Relapsed/Refractory Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for…
Read More...
Read More...
